# A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.

> **NCT00500201** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 18 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SB- 773812 60 mg
- **DRUG:** SB- 773812 120 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00500201
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-24
- **Primary completion:** 2007-07-25
- **Final completion:** 2007-07-25
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500201, "A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00500201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*